Valuation: Cidara Therapeutics

Market Cap 6.96B 6.08B 5.61B 5.16B 9.78B 670B 9.94B 67.01B 26.29B 327B 26.13B 25.56B 1,128B P/E 2023
-3.03x
P/E 2024 -1.01x
Enterprise Value 6.77B 5.92B 5.46B 5.02B 9.51B 652B 9.68B 65.21B 25.59B 319B 25.43B 24.88B 1,098B EV / Sales 2023
0.64x
EV / Sales 2024 84.5x
Free-Float
-
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Director of Finance/CFO 58 24/02/2025
Chief Tech/Sci/R&D Officer - 01/05/2025
Chief Tech/Sci/R&D Officer - 01/05/2025

Financials

2023 2024
Net sales 63.9M 55.87M 51.54M 47.38M 89.77M 6.15B 91.31M 615M 241M 3.01B 240M 235M 10.36B 1.28M 1.11M 1.03M 945K 1.79M 123M 1.82M 12.28M 4.82M 59.96M 4.79M 4.68M 207M
Net income -22.93M -20.05M -18.49M -17M -32.21M -2.21B -32.76M -221M -86.63M -1.08B -86.12M -84.23M -3.72B -170M -148M -137M -126M -239M -16.34B -243M -1.64B -642M -7.99B -638M -624M -27.53B
Net Debt -30.9M -27.02M -24.92M -22.91M -43.41M -2.97B -44.15M -298M -117M -1.45B -116M -114M -5.01B -186M -163M -150M -138M -262M -17.92B -266M -1.79B -704M -8.76B -699M -684M -30.19B
Logo Cidara Therapeutics
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB